Interim Results Presented from Long-Term, Open-Label Extension Study Evaluating Lundbeck Inc. 's ONFI™ (clobazam) in the Adjunctive Treatment of Drop Seizures Associated with LGS

SAVANNAH, Ga.--(BUSINESS WIRE)--Today, Lundbeck Inc. presented interim data from its long-term, open-label extension study evaluating ONFI™ (clobazam) CIV for the adjunctive treatment of drop seizures associated with Lennox-Gastaut syndrome (LGS). These interim results support the reductions in drop seizure rates associated with ONFI when used as add-on therapy for adult and pediatric patients, two years of age or older, with a current or previous diagnosis of LGS.1 Results of this study were presented at the annual meeting of the Child Neurology Society in Savannah, Ga. (Poster No. DD-26). ONFI was approved by the U.S. Food and Drug Administration (FDA) earlier this week for the adjunctive treatment of seizures associated with LGS in patients two years and older.2